ஜீன் பியர் கார்னியர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜீன் பியர் கார்னியர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜீன் பியர் கார்னியர் Today - Breaking & Trending Today

Hope, horror and Covid-19: my 23 years as the Guardian's health correspondent | Health

Hope, horror and Covid-19: my 23 years as the Guardian's health correspondent | Health
theguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theguardian.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , New York , United States , City Of , Glasgow City , Hong Kong , Kwazulu Natal , South Africa , Greenham Common , West Berkshire , Sierra Leone , South African , Martin Godwin , Saddam Hussein , Andrew Wakefield , Peter Duesberg , Pauline Cafferkey , Jean Pierre Garnier , Gabriel Leung , Thabo Mbeki , Yusuf Hamied , Van Dijk , Boris Johnson , Alan Rusbridger , International Aids Conference , World Health Organization ,

CARMAT :'s Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization

CARMAT : s Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization
05/07/2021 | 01:01am EDT
Send by mail :
Message :
Required fields
The Board of Directors warmly thanks Dr. Philippe Pouletty, Managing Director of Truffle Capital, for his exceptional contribution to the development of the CARMAT project, and proposes the appointment of three new directors, Florent Battistella, David Coti and John B. Hernandez.
Regulatory News:
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announced today the reorganization of its governance with the proposed appointment of Florent Battistella, David Coti and John B. Hernandez as directors. Th ....

United States , North Carolina , United Kingdom , Jean Pierre Garnier , Alain Carpentier , Florent Battistella , Ligresti Sant , Philippe Pouletty , Pierre Bastid Lohas , Johnb Hernandez , Economic Affairs , University Of Chapel Hill North Carolina , Airbus Group , Centre Chirurgical Marie Lannelongue , University Of Cambridge , Economic Affairs At Google , Health Economics , Clinical Research , Plekhanov University , Head Of Clinical Research , European Commission , Paul Sabatier University In Toulouse , Boston Scientific , Google Life Sciences , Outcomes Research , Remuneration Committee ,

CARMAT's Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization

CARMAT's Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , North Carolina , United Kingdom , Alain Carpentier , Florent Battistella , Ligresti Sant , Philippe Pouletty , Dusan Oresansky , Johnb Hernandez , Caroline Carmagnol , Jean Pierre Garnier , Pierre Bastid Lohas , Economic Affairs , University Of Chapel Hill North Carolina , Airbus Group , Centre Chirurgical Marie Lannelongue , University Of Cambridge , Economic Affairs At Google , Health Economics , Clinical Research , Plekhanov University , Head Of Clinical Research , European Commission , Paul Sabatier University In Toulouse , Boston Scientific , Google Life Sciences ,

Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript

Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Cellectis SA (NASDAQ: CLLS)
Operator
Greetings. Welcome to the Cellectis Fourth Quarter and Full-Year 2020 Earnings Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.
At this time, I ll turn the conference over to Simon Harnest, Chief Investment Officer. Simon, you may begin.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to ....

France General , North Carolina , United States , Andre Choulika , Hartaj Singh , Jack Allen , Hartaj Singh Oppenheimer , Wangzhi Li , Gena Wang , Salveen Richter Goldman Sachs , Soumit Roy Jones , Soumit Roy , Ingrid Bensinger , Gena Wang Barclays , Salveen Richter , Yigal Nochomovitz , Ingrid Bensinger Kempen , Nick Abbott , Yigal Nochomovitz Citigroup , Simon Harnest , Wangzhi Li Ladenburg , Samantha Corwin William Blair , Carrie Brownstein , Michael Schmidt Guggenheim , Jean Pierre Garnier , Biren Amin ,

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
March 04, 2021 16:42 ET
| Source:
Cellectis Inc.
Cellectis Inc.
New York, New York, UNITED STATES
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers
Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting
Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual Meeting ....

United States , New York , France General , North Carolina , Stanford University , Stephan Grupp , Laurent Poirot , Philippe Duchateau , Cytovia Theraputics , Kyung Nam Wortman , Steve Doares , Iovance Biotherapeutics , Simon Harnest , Mark Frattini , Leopold Bertea , Iovance Biotherapeutic , Carrie Brownstein , Jean Pierre Garnier , Margaret Gandolfo , Conor Mcgoldrick , Head Of Information Technology , Calyxt Inc , American Society Of Clinical Oncology , Clinical Development Appointments , Louis Pasteur University Of Strasbourg , Delta Consulting Group ,